Whether prioritizing internal candidates for further development or deciding which early projects to in-license, choosing the right target is essential to increasing the chance of successfully launching your drug. Selecting the wrong target in early drug discovery can waste time and money, and eventually result in failure of the program. Winning the race to be first-in-class is potentially lucrative but inherently risky, while being best-in-class requires an asset to be clearly differentiated from the competition.
Learn how you can better evaluate targets to avoid wasting resources and missing opportunities while minimizing risks. Watch this webinar to discover best practice approaches and data-driven options.
A scientist will discuss how you can:
- Evaluate the biological evidence for linking a target to a disease of interest
- Monitor the early drug-target landscape and be alerted to potential future threats
- Establish a benchmark for “best-in-class” efficacy and safety
- Make data-driven decisions based on scientific and commercial factors